Malignant gliomas are lethal cancers in the brain and heavily infiltrated by myeloid cells. Interleukin-4 receptor-a (IL-4Ra) mediates the immunosuppressive functions of myeloid cells, and polymorphisms in the IL-4Ra gene are associated with altered glioma risk and prognosis. In this study, we sought to evaluate a hypothesized causal role for IL-4Ra and myeloid suppressor cells in glioma development. In both mouse de novo gliomas and human glioblastoma cases, IL-4Ra was upregulated on glioma-infiltrating myeloid cells but not in the periphery or in normal brain. Mice genetically deficient for IL-4Ra exhibited a slower growth of glioma associated with reduced production in the glioma microenvironment of arginase, a marker of myeloid suppressor cells, which is critical for their T-cell inhibitory function. Supporting this result, investigations using bone marrow-derived myeloid cells showed that IL-4Ra mediates IL-13-induced production of arginase. Furthermore, glioma-derived myeloid cells suppressed T-cell proliferation in an IL-4Ra-dependent manner, consistent with their identification as myeloid-derived suppressor cells (MDSC). Granulocyte macrophage colony-stimulating factor (GM-CSF) plays a central role for the induction of IL-4Ra expression on myeloid cells, and we found that GM-CSF is upregulated in both human and mouse glioma microenvironments compared with normal brain or peripheral blood samples. Together, our findings establish a GM-CSF-induced mechanism of immunosuppression in the glioma microenvironment via upregulation of IL-4Ra on MDSCs. Cancer Res; 73(21); 6413-23. Ó2013 AACR.
Introduction
Malignant gliomas represent approximately 80% of all malignant brain tumors accounting for as many as 26,000 U.S. and European deaths annually, making them a significant unmet medical need (1) . Prognosis for patients with malignant glioma remains dismal with a median survival of approximately 15 months for glioblastoma following surgery and chemo/ radiation therapy (2) . Despite extensive research, treatment options for malignant gliomas remain limited. Although immunotherapeutic approaches have shown safety and promising preliminary activities (3), their effectiveness can be improved by overcoming the immunosuppressive mechanisms induced by these tumors (2) .
Myeloid cells are the most abundant hematopoietic cells in the human body and have diverse functions. Mounting evidence indicates that the tumor microenvironment alters myeloid cells, and the concept of myeloid-derived suppressor cells (MDSC) has emerged (4, 5) . MDSCs represent a heterogenic population of immature myeloid cells (IMC) with an impaired ability to fully develop into macrophages, granulocytes, or dendritic cells and have highly pleiotropic abilities to suppress a variety of T-cell functions and promote tumor growth through effector molecules including arginase (4, 5) .
In mice, MDSCs are identified as cells that simultaneously express the two markers CD11b and Gr1 (6) (7) (8) , and are subdivided into two different subsets based on their expression of the two molecules Ly6C and Ly6G (4) . CD11b
þ Ly-6G À Ly6C high cells have monocytic-like morphology and are termed monocytic-MDSCs (M-MDSC), whereas CD11b þ Ly6G þ Ly6C low cells have granulocyte-like morphology and are termed granulocytic-MDSCs (G-MDSC). In patients with cancer, MDSCs are defined as cells that express the common myeloid marker CD33 but lack markers of mature myeloid cells, such as the human leukocyte antigen (HLA)-DR (9) (10) (11) (12) (13) . Human MDSCs can be divided into at least two subsets that likely parallel those in the mouse model: the CD15 þ G-MDSCs and the CD14 þ M-MDSCs is known to play a role in their immunosuppressive functions (14) (15) (16) (17) . With regard to the roles of myeloid cells in glioma environment (reviewed in ref. 18) , although glioblastoma are highly infiltrated by microglia/macrophages (19) , molecular mechanisms need to be elucidated as to how glioma-infiltrating myeloid cells influence the glioma growth. Recent epidemiology studies have reported that single-nucleotide polymorphisms in IL-4Ra are associated with altered glioma risk and prognosis (20, 21) , suggesting a possibility that IL-4Ra expression on myeloid cells may impact the glioma development. We therefore sought to determine whether IL-4Ra expression on myeloid cells plays a role in glioma development. Here, we show, using a de novo glioma model and human malignant glioma tissues, granulocyte-macrophage colony-stimulating factor (GM-CSF), which is expressed at high levels in the glioma microenvironment, leads to upregulation of IL-4Ra on CD11b þ Gr1 þ IMCs, thereby promoting the induction of arginase via IL-13. Our data show a novel immunosuppressive mechanism in malignant glioma.
Materials and Methods
Animals BALB/c-background wild-type (WT) and Il4ra-deficient mice were obtained from The Jackson Laboratory. Animals were maintained in the Animal Facility at the University of Pittsburgh (Pittsburgh, PA) per an Institutional Animal Care and Use Committee-approved protocol.
Bone marrow MDSC generation
A similar procedure has been previously described (22, 23) . Briefly, red blood cell-depleted bone marrow (BM) cells were isolated from WT or Il4ra À/À mice. Granulocyte colonystimulating factor (G-CSF; 100 ng/mL) and GM-CSF (250 U/mL) were added on days 0, 4, and 9 with IL-13 added (80 ng/mL) on days 4 and 9. All cytokines were purchased from Peprotech. CD11b þ cells were positively selected on day 10 and used in further experiments.
Arginase activity assay
The QuantiChrome arginase assay detection kit (DARG-200) was used according to the manufacturer's instructions, optical density was determined at 430 nm using a multiscan RC plate reader (Thermo Scientific).
MDSC-mediated T-cell Inhibition
CD8 þ T cells were isolated from WT BALB/c splenocytes (SPC) using magnetic bead negative separation (Miltenyi Biotec), labeled with 100 nmol/L carboxyfluorescein diacetate succinimidyl ester (Invitrogen), and incubated with varying amounts of day 10 cultured bone marrow-or glioma-derived MDSCs for 5 days in the presence of anti-CD3/anti-CD28 Dynabeads (Invitrogen) and 30 U/mL of hIL-2 (Peprotech). Cells were then analyzed by flow cytometry on an AccuriC6 (BD Biosciences).
Antibody-mediated immune cell depletion
The procedure has been described previously (8) . Anti-Gr1 (RB6-8C5), anti-CD4 (GK1.5), and anti-CD8 (TIB105) monoclonal antibodies (mAb) were obtained from Taconic; control immunoglobulin G (IgG) was obtained from Sigma-Aldrich. Mice with developing gliomas received intraperitoneal injections of anti-Gr1 (0.25 mg/dose) 3 times per week or anti-CD4 and anti-CD8 (0.5 mg/dose) 2 times per week starting on day 21 after induction of de novo glioma.
Real-time PCR
The procedure has been described previously (7, 8) . Primers and probes were obtained from Applied Biosystems. Human or mouse glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. All reactions were done in triplicate and relative expressions of RNAs compared with control samples were calculated using the DDC t method.
Induction of de novo gliomas by intraventricular transfection of sleeping beauty transposon-flanked proto-oncogenes
The procedure has been described previously (24) . Briefly, DNA transfection reagent (in vivo-jetPEI) was obtained from Polyplus Transfection. The following DNA plasmids were used for glioma induction: pT2/C-Luc//PGK-SB13, pT/CAGGS-NRASV12, pT2/shP53, and PT3.5/CMV-EGFRvIII (0.125 mg for each). For immunologic evaluation of WT and Il4ra À/À tumors, we conducted bioluminescence imaging (BLI) using an IVIS200 (Caliper Life Sciences) and evaluated tumors of comparable size (BLI of 2 Â 10 8 luciferase units).
Bone marrow chimera
Bone marrow chimera experiments were carried out as previously described (25) . Briefly, red blood cell-depleted bone marrow cells were isolated from donor WT or Il4ra À/À mice.
Host BALB/c-background WT mice received 10 Gy of total body irradiation followed by tail vein injection of 1 Â 10 6 viable bone marrow cells. The efficiency of our bone marrow chimera protocol was confirmed to be more than 96% using donor bone marrow cells derived from enhanced GFP transgenic mice ( Supplementary Fig. S1 ).
Isolation of murine brain-infiltrating leukocytes
Brain-infiltrating leukocytes (BIL) were isolated using the methods described previously (7, 26) , using the Percoll (SigmaAldrich) isolation method. Because of the small number of BILs obtained per mouse, BILs obtained from all mice in a given group (5 mice/group) were pooled and then evaluated for the relative number and phenotype of the BILs between groups.
Isolation of human glioma-infiltrating leukocytes and peripheral blood mononuclear cells
De-identified fresh glioma tissues were obtained from the operating room per Institutional Review Board-approved protocol, mechanically minced, resuspended in 70% Percoll (Sigma-Aldrich), overlaid with 37% and 30% Percoll, and centrifuged for 20 minutes at 500 Â g. Enriched leukocyte populations were recovered at the 70% to 37%. Peripheral blood mononuclear cells (PBMC) were isolated from whole blood using a standard Ficoll procedure (Stemcell Technologies).
Statistical analyses
Statistical significance of differences between two groups was determined by Student t test. The log-rank test was used to determine significant differences in survival curves on Kaplan-Meier plots among groups. All data were analyzed by GraphPad Prism (v5.0), P < 0.05 was considered to be statistically significant.
Results

Il4ra
À T-cells deficient of IL-4R or its major signaling molecule STAT-6 are typically skewed toward type-I immune response, which is known to promote antitumor immunity (2, (27) (28) (29) . To exclude a possibility that the prolonged survival of Il4ra À/À mice is solely due to enhanced antitumor T-cell response, we induced Sleeping Beauty gliomas in WT and Il4ra À/À hosts in which CD4 þ and CD8 þ T cells were depleted ( Fig. 1D and Supplementary Fig. S3 ). Although depletion of T cells significantly accelerated the growth of gliomas in both WT and Il4ra À/À mice, Il4ra À/À mice still showed improved SFS over WT mice when both were depleted of T cells. These data show that the improved survival of Il4ra À/À mice is at least partially independent of T cells. Effects of IL-4Ra on the glioma microenvironment and glioma-infiltrating myeloid cells. A, total RNA was isolated from brains of nontumor-bearing mice (normal brain), the contralateral (contra), or tumor-bearing (tumor) hemispheres of brains derived from WT and Il4ra À/À mice. mRNA expression levels of previous studies (7, 8) . To maintain complete depletion, we administered 50 mg/dose anti-Gr1 mAb 3 times per week starting at day 23 ( Fig. 3A; refs. 7, 8 ). Mice depleted of CD11b þ Gr1 þ cells experienced significantly prolonged SFS (Fig. 3B ) with 3 of 7 animals surviving past day 120 (median survival of 74 days), whereas all control mice treated with control isotype IgG died by day 68 (median survival of 55.5 days). BLI revealed that some (n ¼ 3) mice treated with antiGr1 mAb even experienced tumor regression below the level of detection (Fig. 3C) . These data show the importance of CD11b (6, 14) that the IL-13-IL-4Ra signaling mediates T-cell suppressing activities of IMCs via induction of arginase ( Supplementary Fig. S4 ). Notably, WT CD11b 
GM-CSF upregulates IL-4Ra on bone marrow cells and is overexpressed in gliomas
As IL-4Ra expression on CD11b þ Gr1 þ cells is increased in de novo gliomas, we next examined the factors in the glioma microenvironment that lead to the upregulation of IL-4Ra. Bone marrow-derived cells were cultured with G-CSF (100 ng/mL), GM-CSF (250 U/mL), IL-13 (80 ng/mL), or tumor-conditioned media (TCM) from the culture of a de novo glioma-derived cell line for 4 days, and IL-4Ra expression was then measured by (Fig. 5A) . Although G-CSF, GM-CSF, and TCM treatment, all upregulated IL-4Ra expression in three independent experiments, GM-CSF treatment had the most pronounced effect. We thus evaluated our hypothesis that the glioma microenvironment exhibits elevated levels of GM-CSF compared with normal brains or peripheral blood cells. Indeed, in both mouse de novo (Fig. 5B) and human (Fig. 5C ), glioma tissues displayed higher GM-CSF expression levels compared with normal brains, contralateral brains (tested in mice only), and PBMC. When we evaluated the protein levels of GM-CSF in patient-derived glioblastoma tissues by ELISA, we found that the levels (mean of 2.85 ng/g tissue, n ¼ 8; Fig. 5D ) were very similar to those we found effective to promote IL-4Ra upregulation in mouse bone marrow-derived MDSCs in vitro (experiments in Fig. 5A using 250 U/mL; %2.5 ng/mL), suggesting that glioma-derived GM-CSF may be sufficient to induce IL-4Ra on myeloid cells in the glioma microenvironment. (Fig. 6A) . Although glioblastoma tumor-infiltrating leukocytes (TIL) and PBMC cannot be isolated by the same method (see Materials and Methods), using identical forward and side scatter gating on CD14 þ HLA-DR À monocytes in both types of samples, IL-4Ra was detected on 20% to 30% of CD14 þ HLA-DR À TIL, whereas IL-4Ra was barely detectable on corresponding populations in the PBMC. We further examined IL-4Ra expression on frozen glioblastoma TILs (n ¼ 13) and glioblastoma patient-derived PBMC (I ¼ 10; Fig. 6B, left) .
Human glioma-infiltrating CD14
þ cell populations, including those in four matched patient samples (Fig. 6B, right) . We next addressed whether IL-4Ra expression on glioblastoma-infiltrating CD33
HLA-DR
À cells was associated with immune suppressor functions. Using FACS, we isolated IL-4Ra-positive and -negative subpopulations of TILs, extracted total RNA, and analyzed TGFB (Fig. 6C) . IL-4Ra Relative expression Figure 5 . GM-CSF promotes IL-4Ra expression on myeloid cells and is upregulated in human and mouse glioma tissues. Bone marrow cells were cultured in the presence of G-CSF (100 ng/mL), GM-CSF (250 U/mL), IL-13 (80 ng/mL), or TCM for 4 days. A, IL-4Ra expression was determined by flow cytometry. Bars represent the mean and SD of mean fluorescence intensity (MFI) from three independent experiments. B, mouse gmcsf (m-gmcsf) was evaluated from brains of nontumor-bearing mice (brain) or the contralateral (contralateral) or tumor-bearing (glioma) hemispheres of WT mice bearing de novo glioma, relative to brain. C, human GMCSF (h-GMCSF) expression was evaluated in total RNA isolated from healthy donor-derived PBMCs (PBMCs; n ¼ 2), glioma patient-derived PBMCs (gPBMCs; n ¼ 3), normal human brain tissue (brain; n ¼ 3), or glioblastoma tissue (glioblastoma; n ¼ 5), relative to PBMCs. D, GM-CSF levels were evaluated by ELISA in protein extracts of gPBMCs and glioblastoma tissues. Values are adjusted to 1 g of blood (for gPBMCs) or tumor tissue (for glioblastoma).
counterparts. Although we also analyzed the expression of ARG1 and COX2, possibly due to limited numbers of human glioblastoma-infiltrating cells, expression of these molecules was below our limit of detection in both IL-4Ra-positive and -negative CD14 6E ) and IFN-g production (Fig. 6F) , indicating that these cells are indeed MDSCs in glioblastoma. These data strongly suggest that IL-4Ra on CD14 þ HLA-DR À cells in the tumor microenvironment is important for the immunosuppressive activity of these cells.
Discussion
An ideal immunotherapy for gliomas would maximize the therapeutic index by both improving antitumor effector immune cell-functions and inhibiting the immune suppressor cells. Our data show for the first time, in patients with glioblastoma and the de novo murine glioma model, that IL4Ra is upregulated on myeloid cells specifically in the tumor environment but not in the periphery. Although we addressed our main focus on CD11b þ
Gr1
þ/high cells as the most abundant BIL population in the brain (Fig. 1B) , we have also noted that all CD11b þ Gr1 þ cells, including CD11b Our studies using in vitro cultured cells and cells isolated from glioma-bearing hosts collectively suggest that GM-CSF, which is uniquely upregulated in the glioma microenvironment, induces IL-4Ra expression on myeloid cells, thereby facilitating IL-13-induced arginase expression and resulting Tcell suppression. Our data are consistent with a previous report that GM-CSF and the GM-CSF receptor on gliomas correlates with advanced tumor stage (35) . Although we did not examine mechanism of GM-CSF upregulation in human and mouse gliomas, it is possible that GM-CSF may be upregulated through an oncogenic Ras-dependent mechanism (36, 37), which was expressed in our de novo gliomas. Although Ras mutations are uncommon in human gliomas, activation of the Ras pathway is typical via signaling from receptor tyrosine kinases that are often overexpressed in human gliomas. Fig. S5 ), it is likely MDSCs have other non-IL-4Ra-dependent mechanisms of immune suppression, and thus the depletion of Gr1 þ cells may have more robust impacts than the disruption of Il4ra.
In humans, healthy donor-derived human CD14 þ monocytes exposed to glioma cells acquire MDSC-like properties, including increased production of IL-10, TGF-b, and B7-H1, and a heightened ability to induce apoptosis in activated lymphocytes (42) . Patients with glioblastoma have more circulating CD33 þ HLA-DR À MDSCs in their peripheral blood than do normal donors (42, 43) . Furthermore, significant increases in arginase 1 activity levels have been observed in plasma of patients with glioblastoma (43, 44) . Interestingly, T-cell suppression in glioblastoma was completely reversed through the pharmacologic inhibition of arginase 1 or with arginine supplementation (44 (19, 46) , to our knowledge, our current study is one of the first to characterize the phenotype and function of MDSCs in human gliomas. Our findings show a novel mechanism of immunosuppression in the glioma microenvironment. GM-CSF, which is expressed at high levels in both human and mouse gliomas, promotes IL-4Ra expression on glioma-infiltrating myeloid cells with MDSC properties, thereby leading to IL-13-mediated production of arginase. Arginase can then suppress antitumor immune cells, including T cells, thereby promoting the development of glioma growth.
